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Sentinel node biopsy has been established for several years now as a standard procedure of breast cancer surgery, but there are
several variations of the indications and the technique used. This paper provides information regarding several issues of debate
for its application as are the selection criteria, the application to patients with multifocal/multicentric breast cancer or DCIS,
postneoadjuvant chemotherapy, the necessary number of nodes to be biopsied, the need for lymphoscintigraphy, the technique
for frozen section, the factors that may predict nonsentinel nodes (NSNs) involvement, the value of micrometastasis and isolated
tumour cells, the internal mammary chain sentinel nodes, and ﬁnally the axillary recurrence after SLNB. Our view for these issues
is included together with our experience of 430 SLNBs.
1.Introduction
Lymph node status is a key factor in determining the stage
of breast cancer and the most appropriate therapy and for
predicting the outcome of patients. Accurate identiﬁcation
of sentinel lymph nodes (SLNs) preoperatively is of clinical
importance. The results of the NSABP B-32 study indicate
the superiority of the SLNB compared to the ALND treat-
ment approach relative to postsurgical morbidity outcomes
over a 3-year follow-up period [1]. Also the use of ipsilateral
upper arm is not restricted if only SLNB is applied. In
the sentinel lymph node (SLN) era, axillary lymph node
dissection (ALND) for uninvolved axillary lymph nodes
should be considered unnecessary and inappropriate. The
sentinel lymph node biopsy sensitivity is more than 90%,
its speciﬁcity 100%, its accuracy more than 95%, and the
axillary recurrence rate is less than 1%. There are still though
some disputable issues also on this subject.
2. Selection Criteriafor a SLN Biopsy
ASCO Expert Panel published in 2005 guidelines in which
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breast cancer, ductal carcinoma in situ (DCIS) without
mastectomy, nodes suspicious for metastasis, pregnancy,
prioraxillarysurgery,priornononcologicbreastsurgery,and
after preoperative systemic therapy [2]. Is it possible though
to predict to which patients we should not perform the
procedure? According to Lynch et al. [3] there areclinicaland
pathologic features which are associated with a positive SLN,
such as a palpable tumor, increasing tumor size, increasing
histologic grade, and angiolymphatic invasion. Some of the
above features are unreliable and for other we do not have
information always.
Regarding tumor size, SLNB may be acceptable also
for patients with T3 or T4b tumors according to Takei
et al. [4], even though SLN identiﬁcation is lower. Yet SLN
involvement is higher compared with T1 or T2 tumors, and
systemic adjuvant therapy is obviously needed for patients
with T3 or T4b tumors. SLNB is only a bridge to further
axillary treatment such as ALND or axillary RT for those
patients. Clinical examination of the axilla is always the ﬁrst
approach to select the candidate for SLNB. This approach
though, is inaccurate in 41% of cases, false positive in 53%
of patients with moderately suspicious nodes and 23% of
patients with highly suspicious nodes. False positive results2 Pathology Research International
are less frequent with larger tumor size and higher histolog-
ical grade, but are not associated with age, body mass index,
or previous surgical biopsy [5]. Nodes clinically suspicious
formetastasisshouldnotbeconsideredacontraindicationto
SLNB, since palpable axillary lymph nodes can be identiﬁed
and removed by SLNB [4]. It has been recently shown that
by applying the procedure also to patients with clinically
suspicious nodes, after neoadjuvant treatment, large tumors
>2cm, multifocal disease, and previous excisional biopsy the
number of unnecessary ALNDs has been decreased from
26% to 9% [6].
Onewouldconsiderthatthereisnotadiscreteborderline
for the selection criteria and this may be anywhere between
to perform SLNB to “all patients” and to perform it to “only
small tumors with ultrasound guided FNA negative axillary
nodes”.
In our unit candidates for SLNB are all patients with
tumor diameter of less than 3cm, and with negative axilla
bothclinicallyandultrasonographically.Withtheseselection
criteria we have performed 430 SLNBs. The size of less
than 3cm criterion is not supported by the literature, on
the contrary. Being very conservative, we have only recently
m o v e dt oa p p l yS L N Bi na l lT 2t u m o u r s .
3. Multifocal(MF) or Multicentric(MC)
Breast Cancer
In these cases there is an issue when we consider the
diameter of the tumor in relation to the possibility of lymph
node metastasis. Tresserra et al. [7] found that lymph node
metastasisisrelatedonlytothediameterofthelargesttumor.
Ferrarietal.showedthatin93.3%ofpatientswithmultifocal
or multicentric cancer the lymphatic pathways from two
diﬀerent sites of injection converged into one major trunk
leading to the same SLN(s) and in 6.7%, mainly multicentric
cancer, two diﬀerent pathways found each of them leading
to a diﬀerent SLN [8]. The false negative rate was 7.1%
in this study and the authors suggested that both MF and
MC tumors do not represent a contraindication for SLNB.
On the contrary a French prospective multi-institutional
study found that the false negative rate of SLNB for multiple
unilateral synchronous breast cancer was 13.6% which is
unacceptably high even for small tumors [9]. Regarding MC
patients it is generally recommended not to perform SLNB.
Multifocality and multicentricity consist a contraindication
for SLNB in our unit because we aim for a false negative rate
oflessthan5.9%.Thiswasachievedduringthetestingperiod
of the ﬁrst 100 procedures. Multifocal tumours recently are
treated diﬀerently, as we perform SLNB for the largest focus
on a trial’s base.
4. AvoidingSLNB
T h em o s tr e l i a b l es of a rm e t h o dt od e t e c ti n v o l v e da x i l l a r y
nodes is ultrasound and FNA of the suspicious on pal-
pation and/or ultrasound nodes. In the study of Deurloo
et al. this procedure can ﬁnd 31% of all tumor-positive
axillae (macro + micrometastases) and 41% of all axillae
containingmacrometastaseswithmaximumcortexthickness
being the main feature to predict metastatic involvement
[10]. Markedly hypoechoic, thick, or lobulated cortex and
eccentricorabsenceoffattyhillumarethemalignantfeatures
according to Koelliker et al. [11]. Jung et al. found the
sensitivity, speciﬁcity, and positive and negative predictive
values of the ultrasound alone of axillary LNs for metastatic
breast cancer were 54, 91, 75, and 81%, retrospectively. For
the US-FNAC, the respective values were 80, 98, 97, and
84% [12]. AUS with needle biopsy reduces the need for
SLNB by 54% and aﬀects treatment in patients with cT2 or
greater breast cancer [13]. The absence of fatty hillum has
the highest positive predictive value of 93% in the study of
Garcia-Ortega et al. [14]. From the same study the sensitivity
and speciﬁcity of axillary ultrasonography are 63.2% and
88.7%, respectively. The sensitivity and speciﬁcity of axillary
core biopsy are 69.1% and 100%, respectively. With this
proceduresentinellymphnodebiopsycanbeavoidedin33%
of initial candidates and immediate breast reconstruction
was undertaken in 35.1% of the patients with mastectomy
and negative axillary core biopsy. Moreover breast cancer is
frequently characterized by increased 2-ﬂuoro-2-deoxy-D-
glucose uptake, and many studies have shown encouraging
results in detecting axillary lymph node metastases. The
sensitivity of FDG-PET scan for detection of axillary lymph
node metastases in the study of Veronesi et al. [15] was low
(37%); however, speciﬁcity and positive predictive values
were acceptable (96% and 88%, resp.). The high speciﬁcity
of PET imaging indicates that patients who have a PET-
positive axilla should have an ALND rather than an SNB
for axillary staging. In contrast, FDG-PET showed poor
sensitivity in the detection of axillary metastases, conﬁrming
the need for SNB in cases where PET is negative in the
axilla.
Axillary ultrasound has a sensitivity of around 50% and
a speciﬁcity of more than 90% in our hands and therefore we
rely only on the positive results.
5. Neoadjuvant Chemotherapy
So far SLNB is not acceptable for patients with positive
nodes in the axilla at initial diagnosis even if their axillary
metastases are downstaged to negative by neoadjuvant
chemotherapy. In theory, lymphatic mapping may not accu-
rately show whether nodal metastases exist after preoperative
chemotherapy because of excessive ﬁbrosis of the tumour
lymphatics and/or the potential obstruction of lymphatic
channels with cellular material or tumour emboli [16, 17].
Thus, it is important that the feasibility and reliability of
SLNB is determined in this patient group.
Three meta-analyses have been reported that examined
the results of SLNB in patients with breast cancer who did
not receive preoperative chemotherapy [18–20]. The overall
sentinel lymph node identiﬁcation rate (IR) calculated in the
largest of these, determined from data on 28 studies, was
90 per cent. The estimated IR for SLNB after preoperative
chemotherapy in the meta-analysis of Xing et al. [21]i n
whichdatafromthe21studieswereanalyzedwas91percent.
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were similar in pooled analyses suggests that the concerns
mentioned previously [16, 17] are not serious. The estimated
sensitivity of SLNB after preoperative chemotherapy was
88 (95 per cent, credible interval 84 to 91) per cent,
with a false-negative rate of 12 per cent. The overall false
negative rates for SLNB determined in the three separate
meta-analyses of patients who did not receive preoperative
chemotherapy were 8.4 per cent [22], 5.1 per cent [23], and
9p e rc e n t[ 18]. It is still controversial whether SLNB is
acceptable for patients with clinically positive nodes at initial
diagnosis who are treated with neoadjuvant chemotherapy,
whereas SLNB alone is acceptable for patients with an
initial diagnosis of clinically negative axilla who are treated
with neoadjuvant chemotherapy. SLN identiﬁcation rate
was 65% in patients with clinically positive nodes at initial
diagnosis; however, it was 100% in patients with clinically
negative presentation who were treated with neoadjuvant
chemotherapy at M. D. Anderson Cancer Center [24]. On
the other hand proponents of SLNB would argue that in
womenwhohavehadpreoperativechemotherapytheclinical
impact of understaging is less signiﬁcant, given that they
were assigned a clinical stage before chemotherapy and so
the decision to give systemic therapy had already been made.
Thus SLNB after chemotherapy provides information about
residual nodal disease and guides regional therapy. There
is also the consideration of NAC downstaging the axilla,
convertingN1-N2lymphnodestatustoN0andalsoavoiding
full axillary dissection in these patients, provided that the
false negative rate is low as it was found to be 4.3% in the
study of Schwartz et al. [25].
Shimazu et al. [26] proved that intraoperative frozen
section (FS) analysis of SLNs is as accurate for neoadju-
vant chemotherapy-(NAC-)treated as for non-NAC-treated
patients, which indicates that FS analysis of SLNs is
a clinically acceptable method for those receiving NAC.
The application of SLNB- to NAC- treated patients has
been proved to have similar sensitivity, speciﬁcity, and
accuracy to non-NAC-treated patients (74, 100, and 88%,
versus 71, 99, and 90%). The sensitivity of FS analysis for
macrometastases is lower for NAC-treated patients (76%)
than for non-NAC-treated patients (91%), while that for
micrometastases and isolated tumor cells is higher for NAC-
treated patients (67%) than for non-NAC-treated patients
(31%). However, neither of these diﬀerences is statistically
signiﬁcant.
Neoadjuvant chemotherapy can be given not only to
patients with locally advanced breast cancer, but also to
those with axillary lymph node metastasis and an operable
tumor for down-staging and to downsize a tumor in order
to perform conservative surgery. However, SLNB after NAC
results in a lower identiﬁcation rate and a higher FNR than
SLNB before treatment. Recently, a hybrid imaging device
hasbeendeveloped,whichconsistsofsinglephotonemission
computed tomography (CT, SPECT) and a low-dose CT
installed on the same platform. This imaging system oﬀers
an easy and safe method of performing SLNB under local
anesthesia. To identify the initial cancer stage in patients
who will be treated by systemic therapy before surgery, SLNB
should be performed prior to systemic treatments, according
to Iwase et al. [27] by using a well-developed navigating tool,
such as SPECT/CT or the radioguided.
Neoadjuvant chemotherapy or hormone therapy for
operable cancer is still under investigation in our unit and
axillary clearance is a standard procedure for these patients.
6.DCIS
DCIS is pathologically diagnosed only after complete re-
moval of the tumor, and the incidence of accompanying
microinvasion increases when the tumor is palpable and
large, is of high grade, or if the patient is young [28]. The
ASCOguidelinesshowedacutoﬀdiameterof5mmorlarger,
for which SLNB is recommended for patients with an initial
diagnosis of DCIS [2]. In addition, SLNB is recommended
for patients who will undergo mastectomy for the treatment
of DCIS, because the ability to perform SLNB is lost after
removal of the breast.
Our standard procedure is to be prepared and perform
SLNB (radioguided or with blue dye) when frozen section
results show DCIS. We prefer to exhaust our eﬀorts not to
need a second operation, which is necessary in almost 15%
of cases where an inﬁltration or microinﬁltration is found
on ﬁnal histology.
7. Lymphoscintigraphy
The need to perform lymphoscintigraphy prior to SLNB is
another issue. It has been proved beneﬁcial in showing that
at least 1 radioactive SLN will be identiﬁed intraoperatively,
but it does not accurately predict the number of SLN in 40–
50% of the patients [29, 30]. The number of hot spots in
preoperative mapping should serve as a rough indicator of
the smallest number of nodes the surgeon should attempt
to resect, but not the exact number of nodes expected to be
found.
Since we do not do internal mammary chain SLNB, we
ﬁnd lymphoscintigraphy not helpful from the surgical point
of view except in cases with a history of prior sentinel
node, axillary dissection, and plastic surgery. Nevertheless
our nuclear medicine department ﬁnds its images reassuring
for the eﬃcacy of their job.
8. Number of SentinelNodes
The improvement of experience with the blue dye procedure
along with the addition of radioisotope marking of the
SLN contributed to the increase of the number of SLN
are biopsied. Palpable tumors, surgeon’s inexperience, and
dermal injection are associated with greater than 4 SLNs
identiﬁed. All 3 of these factors remain signiﬁcant on
multivariate analysis [31]. Low and littlejohn [32]s u g g e s t
that the optimal number of SLN to harvest, after intradermal
injection of both isotope and blue dye, is two. In their study
33 patients had positive SLN results. If only the ﬁrst SLN was
analyzed, 87.9% of those positive biopsies would have been
discovered. Two SLNs raised the predictive value to 97.0%.
Lynchetal.[3]identiﬁedameannumberof2.86(range,1–8)4 Pathology Research International
SLNs after periareolar injection of radiolabeled technetium
sulfur colloid on the day of surgery. Among the 38 patients
with a positive SLN (30.2%), the hottest node was the ﬁrst
positive SLN in 27 patients (71.1%). The ﬁrst positive SLN
was the ﬁrst node removed in 31 patients (81.6%) and the
second node in 37 patients (97.4%); it was removed in all
patients by the third SLN. These data support the trend of
limiting SLN biopsy to 3 lymph nodes. Removing all SLNs
with radioactive counts greater than 10% of the ex vivo
counts of the hottest SLN does not increase accuracy. The
false negative rates were 14.3% and 4.3% for patients with a
single sentinel node versus multiple sentinel nodes removed,
respectively, in the study of Wong et al. [33]. The blue dye
injection alone was the only factor independently associated
with identiﬁcation of a single SLN and patient age, tumor
size, tumor location, surgeon’s previous experience, and type
of operation were not signiﬁcant.
It is also our ﬁnding that blue dye staining only leads in
most cases to a single SLNB. Our average SLN number is 1.9
by following the rule of 10%.
9. FactorsThat PredictNonsentinel Nodes
(NSNs) Involvement
It is accepted in the community that a positive SLN
frozen section should be followed by ALND. Attempts have
been made to identify factors that predict non sentinel
nodes (NSNs) involvement. The rate of NSNs involvement
increases proportionately to the size of both SN metastases
and primary tumor, while no signiﬁcant correlation was
found for lymphovascular invasion. At univariate and mul-
tivariate analysis of ﬁndings from cases with multiple probe-
detected hot nodes, positivity in more than one hot node
is the strongest predictor of NSN involvement [34]. More
than one positive SLN and a ratio of positive SLNs to total
SLNs of greater than 0.5 were found by Tan et al. [35]t o
be predictors for additional axillary nodal involvement in
both univariate and multivariate analyses. The number of
positive SLNs and the ratio of positive SLNs to total SLNs
is an indication of total tumor burden in the sentinel nodes
and may be a reﬂection of the propensity of the tumor for
further lymphatic invasion in the axillary basin. Another
assumption made is that some patients may beneﬁt from a
more conservative surgical approach to their axillae, perhaps
limited to sentinel node biopsy only or to axillary procedures
restricted to the group of axillary nodes in close proximity
to those designated as sentinel nodes. This assumption was
made when Samoilova et al. [36] found that all patients
with sentinel node tumor deposits < or =5mm had three
or fewer positive nodes; 95% were sentinel node-positive
only, and 91% had single-node involvement. Nine models
have been developed until now to predict non SN status in
patients with SN metastasis. Four models are nomograms:
the Memorial Sloan-Kettering Cancer Center nomogram
(MSKCC nomogram), the Mayo nomogram, the Cambridge
nomogram, and the Stanford nomogram. Three models are
scoring systems: the Tenon score, the score from the M.D.
Anderson Cancer Center (MDA score), and the score of
the group of Saidi. Finally, two are recursive partitioning
tools developed by the group of Kohrt. Those models have
been compared by Coutent et al. [37]. They found that all
models do not perform equally, especially for the subgroup
of patients with only micrometastasis or ITC in the SN
overall,theMSKCCnomogramandTenonscoreoutperform
other methods for all patients, including the subgroup of
patients with only SN micrometastases or ITC, but need
extensive testing before they are put into clinical practice.
A new perspective of non SLN metastasis prediction is the
presence of extracapsular invasion of the SLN and it was
studied by Fujii et al. [38]. It seems to be a strong predictor
of residual disease in the axilla. All cases of positive nodes
in NSLN in these series had extracapsular invasion at the
metastatic SLNs. Furthermore, the absence of ECI of SLN
was signiﬁcantly associated with the absence of metastasis in
the NSLN (P<. 001).
Our experience with 12.5% chance of other non-SLN
inﬁltrated on ALND when one only SLN is inﬁltrated does
not allow us not to proceed to ALND in these circumstances.
The case of only one SLN with microinﬁltration is still under
investigation because of the small number of patients.
10. IntraoperativeAssessment
The need for intraoperative assessment of the SLN is not
under discussion any more as it saves the patient from a
second operation most of the time. False negative rate of
frozensectionisfoundtobe5–25%percent(notsurprisingly
greater for micrometastases) and a second operation cannot
be avoided always. Its sensitivity may be improved by mul-
tilevel sectioning of the lymph node and by histochemistry
[39–41].
Imprint cytology has been tried and is still practiced, but
failed to achieve results similar to frozen section. The meta-
analysis of 31 studies published in 2005 showed that pooled
sensitivity of imprint cytology was 63% and speciﬁcity was
99%. Pooled sensitivity for macrometastases was 81% and
that for micrometastases 22%. Frozen sectioning had better
sensitivity than imprint cytology in three of four direct
comparisons [42]. More recent studies comparing frozen
section and rapid immunohistochemistry to touch imprint
cytology did not change these ﬁndings [43].
Ultrarapid cytokeratin IHC assay is a procedure that does
not exceed 20min. Compared to frozen hematoxylin-eosin
(H&E) stain has a sensitivity of 85% versus 70%, a speciﬁcity
of 100% for both and accuracy rate of 96% versus 92%,
respectively [44]. Ultrarapid IHC may detect also sentinel
node micrometastasis and isolated tumor cells (ITCs) [44–
46]. Serial sections with a spacing of 150 microns between
following sections seems to increase the ability of IHC to
detect ITCs [46]. One Step Nucleic Ampliﬁcation which is a
method that ampliﬁes cytokeratin 19 mRNA and measures
its amount which is directly related to the size of metastatic
foci. This is a procedure that is completed in 30min. In a
multicentric study in Japan it was found that its concordance
ratetothehistochemicalinvestigationis98.2%thespeciﬁcity
is 96.5% [47]. Concerns are raised though for the inability
to determine the actual size of nodal metastases which is
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determine the true false positive and negative rate, since the
tissue has been used for RNA isolation.
Frozen section with ultra rapid cytokeratin IHC is the
way we proceed. In our series SLN was found negative on
H&E and positive on IHC in 3.17% of patients and the
discrepancy between H&E and IHC was signiﬁcantly less
common when more than one SLN were examined (1.6%
versus 3.7%, P<. 01).
11.MicrometastasisandIsolatedTumor Cells
Theimportanceofdetectingmicrometastasis(MM)(0.2mm
–2mm) and isolated tumor cells (ITCs) (<0.2mm) in an
ALN is unknown. Should its detection in a SLN on ultra
rapid IHC lead to ALND? In the study of Dabbs et al.
[48] 13.6% of the patients that were IHC positive had
ALN macrometastasis in a solitary ALN. Of the patients
with micrometastatic SLNs 8.1% had a solitary positive
ALN, 6.1% of which were macrometastases. Overall 9.0%
with traditionally deﬁned SLN micrometastases of 2.0mm
or less had a solitary ALN macrometastasis. There was
a signiﬁcant diﬀerence in the means of SLN tumor sizes
for the SLN-positive/ALND-negative (4.5mm) versus SLN-
positive/ALND-positive (10.1mm) patients. When the 2
recently published interpretations of the TNM deﬁnitions
were applied to cases of low-volume sentinel lymph node
(SLN) involvement and their corresponding non-SLNs for
reclassiﬁcation as micrometastasis or ITC, the rates of
non-SLN metastases associated with SLN ITCs were 8.5%
and 13.5%, respectively [49]. The prognostic impact of
micrometastases and ITCs is still under investigation. Iso-
lated tumour cells or micrometastases in regional lymph
nodes were associated with a reduced 5-year rate of disease-
free survival among women with favourable early-stage
breast cancer who did not receive adjuvant therapy in the
study of de Boer et al. In patients with isolated tumour
cells or micrometastases who received adjuvant therapy,
disease-free survival was improved [50]. Ten-year breast
cancer-speciﬁc survival (BCSS) and overall survival (OS)
in pNmic breast cancer were found by Truong et al. to be
signiﬁcantly lower compared to pN0 disease (BCSS 82.3%
versus 91.9%, P<. 001 and OS 68.1% versus 75.7%, P<
.001) [51]. Park et al. showed that ITC have no impact on
survival at a median 8.2 years of followup, whereas MM
shows a trend toward poorer disease-free survival (DFS)
(P = .091, log rank) and distant disease free survival
(DDFS) (P = .066) and signiﬁcantly reduced BCSS (P =
.016). In multivariate analyses, detection of MM is an
independent prognostic factor for DDFS (P = .025) and
BCSS (P = .01) in adjuvant untreated patients. The evidence
so far shows that micrometastases in axillary lymph nodes
have prognostic impact. This is not found for ITC. Those
ﬁndings support the use of systemic adjuvant therapy in
patients with MM [52]. Axillary recurrence could also be a
threat for those patients, and it was found that one patient
with an SLN micrometastasis (1 of 33; 3%) and 1 patient
with an SLN macrometastasis (1 of 14; 7%) developed an
axillary recurrence with distant metastasis at 84 months
and 28 months, respectively [53]. The group from MSKCC
found that young age, estrogen receptor negative status,
high MSKCC nomogram score, and chemotherapy were
associated with ALND. The practice of selectively limiting
ALND to IHC-only patients thought to be at high risk and
to patients for whom the identiﬁcation of additional positive
nodes may change systemic therapy recommendations seems
to be a safe and reasonable approach. Among patients who
had ALND (n = 95), 18% had a positive non-SLN. No
axillary recurrences were observed in this series with a
medianfollowupof6.4years.Thepercentageofpatientswho
were recurrence-free after 5 years was 97 [54].
There is not though a general agreement for the proper
way of sentinel node specimen handling in order to achieve
ﬁndingallMMandITCs.Thereareinstitutionsdoubtingthe
necessity of multiple level sectioning [55] and other support-
ing the Milan proposal of sectioning at 50-micron intervals
and for each level, one section stained with hematoxylin and
eosin and the other section immunostained for cytokeratins
using a rapid immunocytochemical assay, claiming that this
way the detection of metastases is increased by 7.8% [56–
58]. American College of Pathologists guidelines of 2009
are that the SN should be bivalved along the longitudinal
axis, serially sectioned at 1.5- to 2.0-mm thickness blocks;
each block should be sectioned at 3 levels and examined
using routine H&E stains. They consider controversial the
routineuseofimmunohistochemical(IHC)stainingorother
molecular approaches.
We perform ALND for all patients with MM. We do
not proceed to ALND for patients with ITC if it is the only
positive node among 2 or more SLN. If MM is found on
regular histology we discuss with the patient the options of
doing nothing or having ALND or axillary RT, informing her
also of the existing risk of leaving an inﬁltrated node in her
axilla.
12.InternalMammary ChainSentinelNodes
Lymphatic mapping for sentinel lymph node (SLN) biopsy
has demonstrated extra-axillary drainage in up to 35% of
patients. In the subset of patients with tumours 1cm or less
in size and no ALNM, information on IMN status would
provide important information. In these cases, the presence
of IMN metastases would change the staging from stage I
to stage IIIB, according to the current tumour, node, and
metastasis classiﬁcation. More importantly, it would inﬂu-
ence these patients’ adjuvant treatment [59]. Peritumoral
isotope injection contributes to internal mammary chain
(IMC) sentinel lymph nodes visualization in 28.75% of
patients according to Bourre et al. [60]. IMC biopsy failed
in 4% of patients. IMC sentinel node was inﬁltrated in 4.8%
of biopsies performed. Prophylactic irradiation of the IMC
was indicated in 376 patients. Therefore such information
should make it possible to personalize treatment for patients
with stage cT1 mammary cancer and thereby avoid needless
internal mammary radiation therapy in a large number
of patients (93.4% in this study). By intratumoral isotope
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visualized in 21.5% of patients and could be harvested in
87% from the study of Estourgie [61]. IMC SLN contained
tumor in 17% of those harvested and in 7% IMC nodes
were positive whereas the axilla was tumor free. There was
a change of management in 29% of the patients with a
successful IMC-SLNB, including institution or omission of
radiotherapy to the IMC, adjuvant systemic therapy, or
omission of the axillary node dissection. In the European
Institute of Oncology study IMC nodes were found in 88%
of patients, and 8.8% were positive which modiﬁed the
radiotherapy and systemic treatment [62].
IMC nodes have only lately been a subject of reconsid-
eration in our unit and the same is the site of radiotracer
injection as by the subdermal injection we use IMC nodes
that are not visualized. For the time being we perform a
biopsy from the IMC LNs close to the inner site tumours.
13. AxillaryRecurrenceafter SLNB
The incidence of axillary recurrence after tumor negative
sentinel node biopsy, in the study of Bulte et al. [63], is
0.6% (3/541). An event occurred in the 11% of patients
with a micrometastasis in the sentinel node. This was not
signiﬁcantly diﬀerent from the patients with a tumour-
free sentinel node. In the same study was observed a
non-signiﬁcant diﬀerent risk of distant disease in case of
micrometastases compared to a tumour negative sentinel
node. Also the accuracy of SLNB in multicentric/multifocal
breast cancer was comparable with that observed in unifocal
breast cancer with low false negative rate and no axillary
recurrence in the study of Holwitt et al. [64]. Despite a lower
rate of SLN positivity in patients undergoing SLNB only,
axillary recurrence was not observed and none of the 52
patients experienced axillary recurrence (median followup
4.8 years). In 2008 a meta-analysis was published of 48
selected studies concerning 14959 sentinel node-negative
breast cancer patients followed for a median of 34 months
[65]. Sixty-seven patients developed an axillary recurrence,
resulting in a recurrence rate of 0.3%. The sensitivity of the
sentinel node biopsy was 100%. Uni- and multivariable vari-
able analyses showed that the lowest recurrence rates were
reported in studies performed in cancer centers, in studies
that described the use of (99m)Tc-sulphur colloid, and also
wheninvestigatorsusedthesuperﬁcialinjectiontechniqueor
evaluated the harvested sentinel nodes with haematoxylin-
eosin and immunohistochemistry staining (P<. 01). These
results suggest that the sentinel lymph node procedure is a
reliable and accurate instrument for staging of patients with
early breast cancer.
Following the criteria we have set our axillary recurrence
rate is 0.3% and this happened to one patient who did not
complete chemotherapy.
14. Conclusions
Most of the above discussed issues are still in debate. Large
tumoursizeandmultifocalitynotcontraindicationforSLNB
if we accept a slightly lower identiﬁcation and increased false
negative rate. Axillary ultrasound with FNA or core biopsy is
accepted as helpful, because of its high speciﬁcity, in order to
decrease the number of SLNBs. The role of SLNB in relation
to neoadjuvant chemotherapy is still in debate and the same
applies to DCIS. Lymphoscintigraphy is not helpful. Two
or three are the optimum number of SLNs to be biopsied.
There are no widely accepted rules to predict the non-SLN
metastasis. Frozen section with ultra rapid cytokeratin assay
is the most preferred procedure for its sensitivity in deﬁning
lymph node micrometastasis, which is related to poorer
prognosis. Internal mammary chain SLNB may change the
management in few patients. The axillary recurrence rate
with SLNB is acceptably low and this allows us to try and
expand its indications.
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